ATS' Dermagraft
This article was originally published in The Gray Sheet
Executive Summary
Treatment investigational device exemption for the bioengineered human skin graft in the treatment of diabetic foot ulcers is approved by FDA, according to Advanced Tissue Sciences, which says it will focus on a "small number of centers" while working with the Health Care Financing Administration and other payers to address reimbursement. The treatment IDE study will be conducted concurrently with the firm's ongoing clinical trial ("The Gray Sheet" Aug. 10, In Brief). FDA requested the additional study in June to support the firm's premarket approval application for Dermagraft ("The Gray Sheet" June 15, p. 5)
You may also be interested in...
Apligraf Reduces Healing Time For Diabetic Foot Ulcers By 30%
Organogenesis' Apligraf living skin construct reduces the time it takes diabetic foot ulcers to heal by almost one-third, the company says.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.